Senior Software Engineer - R&D Product Development
About the job
- At least 5–7 years of software engineering experience.
- A track record of leading technical initiatives from concept to production.
- Foundational skills in information technology, including database design, data engineering, cloud computing, and architecture principles.
- The ability to translate sophisticated scientific and business needs into practical technical solutions.
- Experience designing systems that handle regulated or validated data.
- Understanding of GxP or regulated-system requirements.
- Experience with cloud-native platforms and technologies, including Amazon Web Services, AWS Lambda, AWS Step Functions, Docker, and Kubernetes.
- Expertise in application programming interface design, microservices patterns, and event-driven architectures.
- Strong data modeling and schema-evolution expertise.
- Experience with testing strategies and quality-engineering practices.
- Experience establishing engineering practices and tooling across teams.
- Experience using artificial-intelligence-assisted development tools, such as Kiro and Claude Code, to improve engineering efficiency.
- Proficiency in Python for prototyping, integration, or workflow automation.
- Proven experience owning products or platforms throughout their lifecycle in a multi-team environment.
- Strong interpersonal and negotiation skills to influence and build trusted partnerships across functions.
- Experience leading a team of external resources.
- Experience delivering high-quality digital solutions, including dependency management, release planning, change control, validation, and governance.
- Familiarity with software development lifecycle methodologies and software-validation practices.
- Design, build, and support integrations across core business laboratory systems.
- Define and maintain the engineering and technology architecture vision, roadmap, and standards for the Synthetics Development domain.
- Lead technical architecture across squads and ensure alignment with enterprise patterns, reusable components, and modern engineering practices.
- Evaluate, design, and select technical solution options; build, test, and validate architectural concepts and prototypes; and contribute production code to critical technical paths.
- Translate sophisticated business and scientific requirements into scalable and actionable technical designs.
- Drive technical decisions that ensure long-term sustainability.
- Collaborate with platform and product teams to leverage enterprise capabilities, including AWS, data platforms, workflow engines, and laboratory systems.
- Develop a technical understanding of existing laboratory systems, their business use cases, and integration approaches.
- Own continuous integration and continuous delivery pipeline architecture and the automation strategy.
- Establish observability and operational-excellence standards across platforms.
- Manage technical debt and maintain system health through proactive refactoring and modernization.
- Manage development and review cadence and align the technology landscape across squads to promote interoperability, modularity, and scalability.
- Mentor and develop engineering talent across squads.
- Establish engineering standards and review practices.
- Lead technical hiring and team scaling.
- Own lifecycle management for domain technologies, including the Product API catalog and integrations governance.
- Ensure architectural compliance with security, privacy, data-governance, and regulatory standards.
- Establish policies and standards for responsible artificial-intelligence tool usage in regulated and validated environments.
- Monitor emerging technology trends in laboratory automation, cloud engineering, artificial intelligence and machine learning, and scientific computing.
- Conduct research spikes and feasibility assessments for new capabilities relevant to synthetic workflows and workflow automation.
- Experience in pharmaceutical discovery or development environments.
- Experience with laboratory-specific systems such as electronic laboratory notebooks, laboratory information management systems, scientific data management systems, or automation-control software.
About the company
Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
- Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
- Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.
What critics are saying
- Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
- Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
- Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.
What makes Johnson & Johnson unique
- Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
- Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
- Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
-2%1 year growth
-2%2 year growth
-2%Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.
US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.
Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.
Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.
Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.